Canary Staked INJ ETF aims to bring regulated Injective staking to Nasdaq

Canary Capital's amended S-1 lays out a 1.10% fee, a 90% staking target and a $15 million seed commitment from the Injective Foundation Canary Capital wants to give US investors a way to own Injective’s INJ token and collect staking rewards without touching a crypto wallet. The vehicle is the proposed Canary Staked INJ ETF, which would trade on Nasdaq under the ticker INJC, pending approval from the Securities and Exchange Commission. If it clears that hurdle, it would become the first staked INJ ETF in the US. What the filing actually says Canary first filed an S-1 registration statement with the SEC in July 2025. The most recent amendment landed on October 23, 2026, and it fills in many of the operational details. The core plan is simple to describe. The fund would hold INJ, the native token of the Injective network, and stake at least 90% of its assets through third-party providers. Staking is how proof-of-stake networks like Injective keep themselves running. Token holders lock up their coins to help validate transactions, and the network pays them rewards for doing it. Rather than paying staking rewards out to shareholders as cash, the fund plans to reinvest net rewards back i...